Félix Sauvage received his pharmacy degree (Pharm.D) in 2013 at the University of Rouen, France. The same year, he obtained his Master’s degree in Pharmaceutical Technology and Biopharmaceutics at University Paris-Saclay and a fellowship from the French Ministry of Higher Education and Research. He joined the Institut-Galien Paris-Saclay (University Paris-Saclay, France) for a PhD where he worked on the delivery of heat shock protein inhibitors to tumours. In 2017, Félix Sauvage joined the Laboratory of General Biochemistry and Physical Pharmacy headed by Prof. Stefaan De Smedt at Ghent University as a postdoctoral research scientist with a focus on nanotechnology and photonics in ophthalmology. Since 2017, the use of pulsed-lasers in combination with light absorbing nanoparticles for the treatment of corneal and vitreous diseases is his major focus. Since 2016, he published 14 peer-reviewed articles (some of them in recognized journals; Advanced Materials, Advanced Functional Materials, ACS nano), 2 patents and 1 book chapter.

His early-career achievements have been recognized by several organizations. In 2019, he received a young investigator award from the European Association for Vision and Eye Research (EVER). In 2020, Félix received the AMIFAC award of the French Academy of Pharmacy for his work on the use of pulsed-lasers and nanoparticles for the destruction of vitreous opacities. His research is situated at the interface between drug delivery, material sciences, biophysics and biology with a major focus on ophthalmology.